Biopharmaceutical Contract Manufacturing Market: Outsourcing – What Services are Biomanufacturing Directors Looking for from CMOs?

Biopharm

William Downey MBA, President HighTech Business Decisions, Inc. Scott M. Wheelwright, PhD, President Strategic Manufacturing Worldwide, Inc.

Introduction
As the world economy and financial markets contracted in 2009, so did the market for biopharmaceutical contract manufacturer services. As the result of this year-to-year decline, certain biopharmaceutical contract manufacturers (“CMOs”) merged or exited the business. While the shortterm economic events caused dislocations for CMOs, the long-term prospects continue to be positive, as pharmaceutical and biotechnology companies continue to outsource more of their production and seek other additional services from CMOs.

In the latest report by HighTech Business Decisions, Biopharmaceutical Contract Manufacturing: Expanding Markets, New Capacities and Improved Performance, HighTech Business Decisions analysts interviewed 48 pharmaceutical and biotechnology manufacturing directors and executives from 29 biopharmaceutical contract manufacturers. The information for this article draws from interviews with 48 pharmaceutical and biotechnology manufacturing directors covering their observations about contracting the production of their biopharmaceuticals, current services outsourced, and new services that they expect to outsource. ...

http://pharmoutsourcing.com/images/article/4_Wheelwright.pdf